Efficacy and Safety of Etelcalcetide (AMG 416) in the Treatment of Secondary Hyperparathyroidism (SHPT) in Patients With Chronic Kidney Disease (CKD) on Hemodialysis
A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 515 participants.
Also called NCT01788046
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; triple masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 515 participants
- Sponsor
- Registry
-
NCT01788046 -
2012-002806-31
-
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Results first posted
- Countries
- United States, Australia, Belgium, Canada, Czechia, France, Germany, Hungary, Israel, Italy, Netherlands, Poland, Russia, Spain, Sweden
- Registry status
- Completed
Technical summary
Registry record NCT01788046. Randomized; triple masking; primary purpose treatment. Start 2013-03-12 (actual); primary completion 2014-04-14 (actual). Results posted on 2017-03-27.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Efficacy and Safety of Etelcalcetide (AMG 416) in the Treatment of Secondary Hyperparathyroidism (SHPT) in Patients With Chronic Kidney Disease (CKD) on Hemodialysis
- Condition
- Hyperparathyroidism, Secondary
- Intervention (Drug)
- Etelcalcetide
- Intervention (Drug)
- Placebo
- Lead sponsor
- Amgen
Record details
- Record id
cardio:ct-nct01788046- Content hash
299c1e54584fce49353be22e6f9648cfd10a42f7a9b2be1e699a6a827c8326f2